Dihexa Research Overview

Dihexa (developmental code PNB-0408) is a synthetic hexapeptide analog of angiotensin IV, developed at Washington State University by Joseph Harding and colleagues. It was designed to be blood-brain barrier permeable and orally active — a pharmacological improvement over earlier angiotensin IV analogs that were peptidase-labile and poorly bioavailable. In rodent models of cognitive impairment, Dihexa has produced striking reversal of scopolamine-induced deficits and increased hippocampal spinogenesis. It is sold by research compound vendors as a nootropic peptide. There are zero completed human clinical trials of Dihexa; every benefit claim in humans is anecdotal or extrapolated from animal work.

What Is Dihexa?

Dihexa is chemically designated as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. It is a six-residue peptide with a hexanoic acid cap at the N-terminus, which confers resistance to aminopeptidases compared to linear peptide analogs. Its molecular weight is approximately 605 Da, small enough for potential CNS penetration. It was derived from iterative structural optimization of angiotensin IV (AngIV) and its analog Norleucine1-angiotensin IV (Nle1-AngIV).

Dihexa was developed in the laboratory of Joseph W. Harding at Washington State University. Alene T. McCoy was a primary author on the 2013 publication documenting its procognitive effects (McCoy et al., JPET 2013). The compound is CAS-registered under CAS 1401708-83-5. It has no INN and no FDA IND on public record.

Mechanism of Action

Dihexa binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor. HGF/c-Met signaling plays a well-established role in synaptic plasticity, dendritic arborization, and neuronal survival. By acting as a positive allosteric potentiator of HGF, Dihexa amplifies endogenous HGF signaling at subthreshold HGF concentrations, augmenting synaptogenesis and spinogenesis in hippocampal neurons.

In hippocampal neuron culture experiments, Dihexa and its parent compound Nle1-AngIV produced dendritic spine density increases similar to HGF itself. Potency comparisons to BDNF in synaptogenesis assays have been reported at extremely large multiples (sometimes cited as 10 million-fold), though this figure requires careful interpretation: it reflects a specific assay readout under specific conditions and should not be generalized to mean that Dihexa is therapeutically superior to BDNF in any clinical sense.

An important caveat: The 2014 Benoist et al. paper that provided key mechanistic support for the HGF/c-Met mechanism was retracted in April 2025 due to concerns about image manipulation involving a co-author. This does not invalidate the broader AngIV/c-Met literature, but it does reduce certainty about the precise mechanistic claims in that specific paper.

What the Research Shows

All completed research on Dihexa is preclinical. The key study is McCoy et al. (2013), published in the Journal of Pharmacology and Experimental Therapeutics. This paper demonstrated that oral Dihexa (2 mg/kg) reversed scopolamine-induced cognitive deficits in rats by day 7, with performance statistically indistinguishable from unimpaired controls. The compound was active orally and showed CNS penetration, addressing the main pharmacokinetic limitations of earlier AngIV analogs.

Additional rodent studies have evaluated Dihexa in models of Alzheimer's-like amyloid pathology and in aged cognitively impaired rats. Results were generally positive for memory and spatial learning tasks. Synaptogenesis data from hippocampal neuron culture models supported the structural interpretation of these behavioral findings.

There are no registered or completed Phase 1, 2, or 3 human clinical trials of Dihexa as of the date of this guide. No human pharmacokinetic data, safety data, or efficacy data have been published in peer-reviewed literature. The compound is widely sold by research peptide vendors and discussed extensively in nootropic communities with claims that routinely exceed what the rodent data can support. Researchers should treat all human-specific claims with strong skepticism.

One further honest note: HGF/c-Met is a growth factor pathway with known roles in tumor progression and angiogenesis. The long-term safety implications of potentiating this pathway, particularly in individuals with subclinical or undiagnosed malignancy, are entirely unknown in humans.

Pharmacokinetics

In rodents, Dihexa is orally bioavailable and brain-penetrant. The hexanoic acid cap confers resistance to aminopeptidase degradation, significantly improving metabolic stability compared to unmodified AngIV. Behavioral effects in rodent models have been observed following oral gavage at 2 mg/kg. The specific PK parameters — Cmax, Tmax, elimination half-life, volume of distribution — in rodents have not been comprehensively published in peer-reviewed sources. No human PK data exist.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The only published dosing data for Dihexa comes from rodent studies. Oral doses of 2 mg/kg reversed cognitive deficits in the McCoy et al. (2013) scopolamine model. Simple mg/kg extrapolation from rodents to humans is scientifically unreliable and cannot produce meaningful human dose estimates. No human dosing has been studied in any controlled setting. Vendor-provided dosing guidelines are not derived from clinical trial data.

Storage and Handling

Dihexa is available as a lyophilized powder or in some vendor formulations as a nasal spray or oral solution. Lyophilized Dihexa should be stored at -20 °C, protected from moisture and light. Once reconstituted in sterile water, refrigerate at 2–8 °C and use within 28 days. Avoid repeated freeze-thaw cycles. Handling should be performed in a clean laboratory environment; appropriate personal protective equipment should be used, as no human toxicity profile has been established.

What Dihexa Is NOT

Dihexa is not a proven cognitive enhancer in humans. It is not FDA-approved or investigational in any registered trial. It is not angiotensin IV, HGF, or BDNF. It is not a safe alternative to established treatments for Alzheimer's disease or cognitive decline. The striking rodent findings have not been confirmed in primate or human studies, and the preclinical evidence base has a partially retracted mechanistic component. The gap between preclinical performance and human translation is often very large in CNS pharmacology; Dihexa has not bridged this gap.

References

1. McCoy AT et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141–154. PMID 23115221.

2. Harding JW. Procognitive effects of angiotensin IV and its analogs at Washington State University. Multiple publications 2000–2014.

3. Benoist CC et al. (2014) — Note: This paper providing detailed HGF/c-Met mechanism was retracted April 2025 due to image manipulation concerns. Cited for historical reference only.